{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T20:47:10Z","timestamp":1771879630171,"version":"3.50.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T00:00:00Z","timestamp":1756944000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T00:00:00Z","timestamp":1756944000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Rheumatol"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s00393-025-01703-2","type":"journal-article","created":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T12:53:05Z","timestamp":1756990385000},"page":"601-611","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Chim\u00e4re Antigen-Rezeptor-T-Zellen f\u00fcr Patientinnen und Patienten mit h\u00e4matologischen Neoplasien","Chimeric antigen receptor T-cells for patients with hematologic malignancies"],"prefix":"10.1007","volume":"84","author":[{"given":"Maria-Luisa","family":"Schubert","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Dreger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Schmitt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,4]]},"reference":[{"key":"1703_CR1","unstructured":"https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/kymriah-epar-product-information_en.pdf"},{"key":"1703_CR2","unstructured":"https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/yescarta-epar-product-information_en.pdf"},{"key":"1703_CR3","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1056\/NEJMoa2301665","volume":"389","author":"JR Westin","year":"2023","unstructured":"Westin\u00a0JR, Oluwole\u00a0OO, Kersten\u00a0MJ, Miklos\u00a0DB, Perales\u00a0MA, Ghobadi\u00a0A, Rapoport\u00a0AP, Sureda\u00a0A, Jacobson\u00a0CA, Farooq\u00a0U et\u00a0al (2023) Survival with Axicabtagene Ciloleucel in Large B\u2011Cell Lymphoma. N\u00a0Engl J Med 389:148\u2013157. https:\/\/doi.org\/10.1056\/NEJMoa2301665","journal-title":"N Engl J Med"},{"key":"1703_CR4","unstructured":"https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/tecartus-epar-product-information_en.pdf"},{"key":"1703_CR5","unstructured":"https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/breyanzi-epar-product-information_en.pdf"},{"key":"1703_CR6","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1182\/blood.2022018730","volume":"141","author":"JS Abramson","year":"2023","unstructured":"Abramson\u00a0JS, Solomon\u00a0SR, Arnason\u00a0J, Johnston\u00a0PB, Glass\u00a0B, Bachanova\u00a0V, Ibrahimi\u00a0S, Mielke\u00a0S, Mutsaers\u00a0P, Hernandez-Ilizaliturri\u00a0F et\u00a0al (2023) Lisocabtagene maraleucel as second-line therapy for large B\u2011cell lymphoma: primary analysis of the phase\u00a03 TRANSFORM study. Blood 141:1675\u20131684. https:\/\/doi.org\/10.1182\/blood.2022018730","journal-title":"Blood"},{"key":"1703_CR7","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1111\/ejh.13380","volume":"104","author":"N Gagelmann","year":"2020","unstructured":"Gagelmann\u00a0N, Ayuk\u00a0F, Atanackovic\u00a0D, Kr\u00f6ger\u00a0N (2020) B\u00a0cell maturation antigen-specific chimeric antigen receptor T\u00a0cells for relapsed or refractory multiple myeloma: A\u00a0meta-analysis. Eur J Haematol 104:318\u2013327. https:\/\/doi.org\/10.1111\/ejh.13380","journal-title":"Eur J Haematol"},{"key":"1703_CR8","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi\u00a0NC, Anderson\u00a0LD Jr., Shah\u00a0N, Madduri\u00a0D, Berdeja\u00a0J, Lonial\u00a0S, Raje\u00a0N, Lin\u00a0Y, Siegel\u00a0D, Oriol\u00a0A et\u00a0al (2021) Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. N\u00a0Engl J Med 384:705\u2013716. https:\/\/doi.org\/10.1056\/NEJMoa2024850","journal-title":"N Engl J Med"},{"key":"1703_CR9","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1080\/03007995.2021.1953456","volume":"37","author":"T Martin","year":"2021","unstructured":"Martin\u00a0T, Usmani\u00a0SZ, Schecter\u00a0JM, Vogel\u00a0M, Jackson\u00a0CC, Deraedt\u00a0W, Tian\u00a0H, Yeh\u00a0TM, Banerjee\u00a0A, Pacaud\u00a0L et\u00a0al (2021) Matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE\u20111 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma. Curr Med Res Opin 37:1779\u20131788. https:\/\/doi.org\/10.1080\/03007995.2021.1953456","journal-title":"Curr Med Res Opin"},{"key":"1703_CR10","unstructured":"https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/carvykti-epar-product-information_en.pdf"},{"key":"1703_CR11","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s13045-023-01470-0","volume":"16","author":"ML Schubert","year":"2023","unstructured":"Schubert\u00a0ML, Schmitt\u00a0A, H\u00fcckelhoven-Krauss\u00a0A, Neuber\u00a0B, Kunz\u00a0A, Waldhoff\u00a0P, Vonficht\u00a0D, Yousefian\u00a0S, Jopp-Saile\u00a0L, Wang\u00a0L et\u00a0al (2023) Treatment of adult ALL patients with third-generation CD19-directed CAR T\u00a0cells: results of a\u00a0pivotal trial. J\u00a0Hematol Oncol 16:79. https:\/\/doi.org\/10.1186\/s13045-023-01470-0","journal-title":"J Hematol Oncol"},{"key":"1703_CR12","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1038\/s41375-024-02392-7","volume":"38","author":"P Derigs","year":"2024","unstructured":"Derigs\u00a0P, Schubert\u00a0M\u2011L, Dreger\u00a0P, Schmitt\u00a0A, Yousefian\u00a0S, Haas\u00a0S, R\u00f6themeier\u00a0C, Neuber\u00a0B, H\u00fcckelhoven-Krauss\u00a0A, Br\u00fcggemann\u00a0M et\u00a0al (2024) Third-generation anti-CD19 CAR T\u00a0cells for relapsed\/refractory chronic lymphocytic leukemia: a\u00a0phase\u00a01\/2\u00a0study. Leukemia 38:2419\u20132428. https:\/\/doi.org\/10.1038\/s41375-024-02392-7","journal-title":"Leukemia"},{"key":"1703_CR13","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","volume":"28","author":"A Mackensen","year":"2022","unstructured":"Mackensen\u00a0A, M\u00fcller\u00a0F, Mougiakakos\u00a0D, B\u00f6ltz\u00a0S, Wilhelm\u00a0A, Aigner\u00a0M, V\u00f6lkl\u00a0S, Simon\u00a0D, Kleyer\u00a0A, Munoz\u00a0L et\u00a0al (2022) Anti-CD19 CAR T\u00a0cell therapy for refractory systemic lupus erythematosus. Nat Med 28:2124\u20132132. https:\/\/doi.org\/10.1038\/s41591-022-02017-5","journal-title":"Nat Med"},{"key":"1703_CR14","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1056\/NEJMoa2308917","volume":"390","author":"F M\u00fcller","year":"2024","unstructured":"M\u00fcller\u00a0F, Taubmann\u00a0J, Bucci\u00a0L, Wilhelm\u00a0A, Bergmann\u00a0C, V\u00f6lkl\u00a0S, Aigner\u00a0M, Rothe\u00a0T, Minopoulou\u00a0I, Tur\u00a0C et\u00a0al (2024) CD19 CAR T\u2011Cell Therapy in Autoimmune Disease\u2014A Case Series with Follow-up. N\u00a0Engl J Med 390:687\u2013700. https:\/\/doi.org\/10.1056\/NEJMoa2308917","journal-title":"N Engl J Med"},{"key":"1703_CR15","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1136\/ard-2023-225174","volume":"83","author":"W Merkt","year":"2024","unstructured":"Merkt\u00a0W, Freitag\u00a0M, Claus\u00a0M, Kolb\u00a0P, Falcone\u00a0V, R\u00f6hrich\u00a0M, Rodon\u00a0L, Deicher\u00a0F, Andreeva\u00a0I, Tretter\u00a0T et\u00a0al (2024) Third-generation CD19.CAR-T\u00a0cell-containing combination therapy in Scl70+ systemic sclerosis. Ann Rheum Dis 83:543\u2013546. https:\/\/doi.org\/10.1136\/ard-2023-225174","journal-title":"Ann Rheum Dis"},{"key":"1703_CR16","first-page":"OS14","volume-title":"51st\u00a0Annual Meeting of the EBMT, April\u00a01, 2025; Florence","author":"K Farid","year":"2025","unstructured":"Farid\u00a0K, Hegenbart\u00a0U, Sch\u00f6nland\u00a0S, Raab\u00a0M, Neuber\u00a0B, H\u00fcckelhoven-Krauss\u00a0A, Cla\u00dfen\u00a0L, Busch\u00a0E, M\u00fcller-Tidow\u00a0C, Dreger\u00a0P et\u00a0al (2025) Successful treatment of patients with heavily tretreated systemic light chain AL amyloidosis and multiple myeloma with the novel MDC-BCMA-CAR-001. In: 51st\u00a0Annual Meeting of the EBMT, April\u00a01, 2025; Florence, S\u00a0OS14\u20136 (Conference presentation abstract)"},{"key":"1703_CR17","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/s0140-6736(21)00933-8","volume":"398","author":"JG Berdeja","year":"2021","unstructured":"Berdeja\u00a0JG, Madduri\u00a0D, Usmani\u00a0SZ, Jakubowiak\u00a0A, Agha\u00a0M, Cohen\u00a0AD, Stewart\u00a0AK, Hari\u00a0P, Htut\u00a0M, Lesokhin\u00a0A et\u00a0al (2021) Ciltacabtagene autoleucel, a\u00a0B-cell maturation antigen-directed chimeric antigen receptor T\u2011cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a\u00a0phase\u00a01b\/2 open-label study. Lancet 398:314\u2013324. https:\/\/doi.org\/10.1016\/s0140-6736(21)00933-8","journal-title":"Lancet"},{"key":"1703_CR18","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee\u00a0DW, Santomasso\u00a0BD, Locke\u00a0FL, Ghobadi\u00a0A, Turtle\u00a0CJ, Brudno\u00a0JN, Maus\u00a0MV, Park\u00a0JH, Mead\u00a0E, Pavletic\u00a0S et\u00a0al (2019) ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. Biol Blood Marrow Transplant 25:625\u2013638. https:\/\/doi.org\/10.1016\/j.bbmt.2018.12.758","journal-title":"Biol Blood Marrow Transplant"},{"key":"1703_CR19","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude\u00a0SL, Laetsch\u00a0TW, Buechner\u00a0J, Rives\u00a0S, Boyer\u00a0M, Bittencourt\u00a0H, Bader\u00a0P, Verneris\u00a0MR, Stefanski\u00a0HE, Myers\u00a0GD et\u00a0al (2018) Tisagenlecleucel in Children and Young Adults with B\u2011Cell Lymphoblastic Leukemia. N\u00a0Engl J Med 378:439\u2013448. https:\/\/doi.org\/10.1056\/NEJMoa1709866","journal-title":"N Engl J Med"},{"key":"1703_CR20","doi-asserted-by":"publisher","first-page":"877477","DOI":"10.3389\/fimmu.2022.877477","volume":"13","author":"F Korell","year":"2022","unstructured":"Korell\u00a0F, Penack\u00a0O, Mattie\u00a0M, Schreck\u00a0N, Benner\u00a0A, Krzykalla\u00a0J, Wang\u00a0Z, Schmitt\u00a0M, Bullinger\u00a0L, M\u00fcller-Tidow\u00a0C et\u00a0al (2022) EASIX and Severe Endothelial Complications After CD19\u2014Directed CAR-T\u00a0Cell Therapy\u2011A Cohort Study. Front Immunol 13:877477. https:\/\/doi.org\/10.3389\/fimmu.2022.877477","journal-title":"Front Immunol"},{"key":"1703_CR21","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.annonc.2020.10.478","volume":"32","author":"ML Schubert","year":"2021","unstructured":"Schubert\u00a0ML, Schmitt\u00a0M, Wang\u00a0L, Ramos\u00a0CA, Jordan\u00a0K, M\u00fcller-Tidow\u00a0C, Dreger\u00a0P (2021) Side-effect management of chimeric antigen receptor (CAR) T\u2011cell therapy. Ann Oncol 32:34\u201348. https:\/\/doi.org\/10.1016\/j.annonc.2020.10.478","journal-title":"Ann Oncol"},{"key":"1703_CR22","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/s1470-2045(18)30864-7","volume":"20","author":"FL Locke","year":"2019","unstructured":"Locke\u00a0FL, Ghobadi\u00a0A, Jacobson\u00a0CA, Miklos\u00a0DB, Lekakis\u00a0LJ, Oluwole\u00a0OO, Lin\u00a0Y, Braunschweig\u00a0I, Hill\u00a0BT, Timmerman\u00a0JM et\u00a0al (2019) Long-term safety and activity of axicabtagene ciloleucel in refractory large B\u2011cell lymphoma (ZUMA-1): a\u00a0single-arm, multicentre, phase\u00a01\u20132\u00a0trial. Lancet Oncol 20:31\u201342. https:\/\/doi.org\/10.1016\/s1470-2045(18)30864-7","journal-title":"Lancet Oncol"},{"key":"1703_CR23","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","volume":"22","author":"EC Morris","year":"2022","unstructured":"Morris\u00a0EC, Neelapu\u00a0SS, Giavridis\u00a0T, Sadelain\u00a0M (2022) Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. Nat Rev Immunol 22:85\u201396. https:\/\/doi.org\/10.1038\/s41577-021-00547-6","journal-title":"Nat Rev Immunol"},{"key":"1703_CR24","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1182\/bloodadvances.2020001626","volume":"4","author":"NN Shah","year":"2020","unstructured":"Shah\u00a0NN, Johnson\u00a0BD, Fenske\u00a0TS, Raj\u00a0RV, Hari\u00a0P (2020) Intrathecal chemotherapy for management of steroid-refractory CAR T\u2011cell-associated neurotoxicity syndrome. Blood Adv 4:2119\u20132122. https:\/\/doi.org\/10.1182\/bloodadvances.2020001626","journal-title":"Blood Adv"},{"key":"1703_CR25","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1007\/s40263-018-0582-9","volume":"32","author":"J Gust","year":"2018","unstructured":"Gust\u00a0J, Taraseviciute\u00a0A, Turtle\u00a0CJ (2018) Neurotoxicity Associated with CD19-Targeted CAR-T\u00a0Cell Therapies. Cns Drugs 32:1091\u20131101. https:\/\/doi.org\/10.1007\/s40263-018-0582-9","journal-title":"Cns Drugs"},{"key":"1703_CR26","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1093\/jnci\/djz017","volume":"111","author":"BD Hunter","year":"2019","unstructured":"Hunter\u00a0BD, Jacobson\u00a0CA (2019) CAR T\u2011Cell Associated Neurotoxicity: Mechanisms, Clinicopathologic Correlates, and Future Directions. J\u00a0Natl Cancer Inst 111:646\u2013654. https:\/\/doi.org\/10.1093\/jnci\/djz017","journal-title":"J Natl Cancer Inst"},{"key":"1703_CR27","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci14121220","author":"L Palazzo","year":"2024","unstructured":"Palazzo\u00a0L, Pieri\u00a0V, Berzero\u00a0G, Filippi\u00a0M (2024) CAR\u2011T Cells for the Treatment of Central Nervous System Tumours: Known and Emerging Neurotoxicities. Brain Sci. https:\/\/doi.org\/10.3390\/brainsci14121220","journal-title":"Brain Sci"},{"key":"1703_CR28","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/s41408-022-00629-1","volume":"12","author":"AD Cohen","year":"2022","unstructured":"Cohen\u00a0AD, Parekh\u00a0S, Santomasso\u00a0BD, G\u00e1llego P\u00e9rez-Larraya\u00a0J, van de Donk\u00a0N, Arnulf\u00a0B, Mateos\u00a0MV, Lendvai\u00a0N, Jackson\u00a0CC, De Braganca\u00a0KC et\u00a0al (2022) Incidence and management of CAR\u2011T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies. Blood Cancer\u00a0J 12:32. https:\/\/doi.org\/10.1038\/s41408-022-00629-1","journal-title":"Blood Cancer J"},{"key":"1703_CR29","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1182\/blood.2023020578","volume":"142","author":"K Rejeski","year":"2023","unstructured":"Rejeski\u00a0K, Subklewe\u00a0M, Aljurf\u00a0M, Bachy\u00a0E, Balduzzi\u00a0A, Barba\u00a0P, Bruno\u00a0B, Benjamin\u00a0R, Carrabba\u00a0MG, Chabannon\u00a0C et\u00a0al (2023) Immune effector cell-associated hematotoxicity: EHA\/EBMT consensus grading and best practice recommendations. Blood 142:865\u2013877. https:\/\/doi.org\/10.1182\/blood.2023020578","journal-title":"Blood"},{"key":"1703_CR30","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2025028833","author":"K Rejeski","year":"2025","unstructured":"Rejeski\u00a0K, Sanz\u00a0J, Fei\u00a0T, Nair\u00a0MS, Hashmi\u00a0H, Avigdor\u00a0A, Beyar-Katz\u00a0O, B\u00fccklein\u00a0VL, Curran\u00a0KJ, Einarsdottir\u00a0S et\u00a0al (2025) T\u2011ICAHT: Grading and Prognostic Impact of Thrombocytopenia After CAR T\u2011cell Therapy. Blood. https:\/\/doi.org\/10.1182\/blood.2025028833","journal-title":"Blood"},{"key":"1703_CR31","doi-asserted-by":"publisher","first-page":"4690","DOI":"10.1158\/1078-0432.Ccr-24-1798","volume":"30","author":"T Tix","year":"2024","unstructured":"Tix\u00a0T, Alhomoud\u00a0M, Shouval\u00a0R, Cliff\u00a0ERS, Perales\u00a0MA, Cordas Dos\u00a0SDM, Rejeski\u00a0K (2024) Second Primary Malignancies after CAR T\u2011Cell Therapy: A\u00a0Systematic Review and Meta-analysis of 5,517 Lymphoma and Myeloma Patients. Clin Cancer Res 30:4690\u20134700. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-24-1798","journal-title":"Clin Cancer Res"},{"key":"1703_CR32","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1038\/s41591-024-03458-w","volume":"31","author":"R Dulery","year":"2025","unstructured":"Dulery\u00a0R, Guiraud\u00a0V, Choquet\u00a0S, Thieblemont\u00a0C, Bachy\u00a0E, Barete\u00a0S, Todesco \u00c8, Arnulf\u00a0B, Boissel\u00a0N, Baruchel\u00a0A et\u00a0al (2025) T\u00a0cell malignancies after CAR T\u00a0cell therapy in the DESCAR\u2011T registry. Nat Med 31:1130\u20131133. https:\/\/doi.org\/10.1038\/s41591-024-03458-w","journal-title":"Nat Med"},{"key":"1703_CR33","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/s44321-024-00183-2","volume":"17","author":"P Berg","year":"2025","unstructured":"Berg\u00a0P, Ruppert-Seipp\u00a0G, M\u00fcller\u00a0S, Maurer\u00a0GD, Hartmann\u00a0J, Holtick\u00a0U, Buchholz\u00a0CJ, Funk\u00a0MB (2025) CAR T\u2011cell-associated secondary malignancies challenge current pharmacovigilance concepts. EMBO Mol Med 17:211\u2013218. https:\/\/doi.org\/10.1038\/s44321-024-00183-2","journal-title":"EMBO Mol Med"},{"key":"1703_CR34","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1056\/NEJMoa2402730","volume":"391","author":"G Kobbe","year":"2024","unstructured":"Kobbe\u00a0G, Br\u00fcggemann\u00a0M, Baermann\u00a0BN, Wiegand\u00a0L, Trautmann\u00a0H, Yousefian\u00a0S, Libertini\u00a0S, Menssen\u00a0HD, Maier\u00a0HJ, Ulrich\u00a0P et\u00a0al (2024) Aggressive Lymphoma after CD19 CAR T\u2011Cell Therapy. N\u00a0Engl J Med 391:1217\u20131226. https:\/\/doi.org\/10.1056\/NEJMoa2402730","journal-title":"N Engl J Med"},{"issue":"9","key":"1703_CR35","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1002\/ijc.31147","volume":"142","author":"ML Schubert","year":"2018","unstructured":"Schubert\u00a0ML, Hoffmann\u00a0JM, Dreger\u00a0P, M\u00fcller-Tidow\u00a0C, Schmitt\u00a0M (2018) Chimeric antigen receptor transduced T\u00a0cells: Tuning up for the next generation. Int J Cancer 142(9):1738\u20131747","journal-title":"Int J Cancer"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-025-01703-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00393-025-01703-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-025-01703-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T10:06:23Z","timestamp":1759313183000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00393-025-01703-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,4]]},"references-count":35,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["1703"],"URL":"https:\/\/doi.org\/10.1007\/s00393-025-01703-2","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,4]]},"assertion":[{"value":"16 July 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"M.-L.\u00a0Schubert, P.\u00a0Dreger und M.\u00a0Schmitt geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}